Osteoporosis and Metabolic Bone Diseases of the Elderly

  • Lora Giangregorio
  • Alexandra PapaioannouEmail author


Metabolic bone diseases, particularly ­osteo­porosis, are extremely consequential in the elderly population. The chapter details some of the recent advances in the diagnosis and treatment of osteoporosis, osteomalacia, and Paget’s disease. The role of nondrug therapies will also be explored.


Osteoporosis Paget’s disease Osteomalacia Bisphosphonates Metabolic bone disease Nondrug therapies 


  1. 1.
    Baron R. General principles of bone biology. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research; 2003. p. 1–8.Google Scholar
  2. 2.
    Lee CA, Einhorn TA. The bone organ system. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic; 2001. p. 3–20.CrossRefGoogle Scholar
  3. 3.
    Hellekson KL. NIH releases statement on osteoporosis prevention, diagnosis, and therapy. Am Fam Physician. 2002;66(1):161–2.PubMedGoogle Scholar
  4. 4.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Leslie WD, Tsang JF, Lix LM. Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program. Bone. 2008;43(4):667–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Cooper C, Campion G, Melton III LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res. 2005;20(6):898–905.PubMedCrossRefGoogle Scholar
  10. 10.
    Lofman O, Berglund K, Larsson L, Toss G. Changes in hip fracture epidemiology: redistribution between ages, genders and fracture types. Osteoporos Int. 2002;13(1):18–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Papaioannou A, Wiktorowicz ME, Adachi JD, Goeree R, Papadimitropoulos E, Bedard M, et al. Mortality, independence in living and re-fracture, one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can. 2000;22(8):591–7.Google Scholar
  12. 12.
    Petrella RJ, Payne M, Myers A, Overend T, Chesworth B. Physical function and fear of falling after hip fracture rehabilitation in the elderly. Am J Phys Med Rehabil. 2000;79(2):154–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2001;12(11):903–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N. Diagnosis and management of vertebral fractures in elderly adults. Am J Med. 2002;113(3):220–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001;12(4):271–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ. 2000;320(7231):341–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G, Jurriaans E, et al. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int. 2003;14(11):913–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Olszynski WP, Shawn DK, Adachi JD, Brown JP, Cummings SR, Hanley DA, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther. 2004;26(1):15–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156): 878–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int. 2000;11(8):680–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawka AM, Goltzman D, et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008;19(4):581–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Castel H, Bonneh DY, Sherf J, Liel Y. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporosis International. 2001;12:559–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Juby AB, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporosis International. 2002;13:205–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003;23:190–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115(5):398–400.PubMedCrossRefGoogle Scholar
  29. 29.
    Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, et al. Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol. 2004;31(10):1993–5.PubMedGoogle Scholar
  30. 30.
    Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc. 1991;39(8):766–71.PubMedGoogle Scholar
  31. 31.
    Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging. 2008;3(1):25–44.PubMedGoogle Scholar
  32. 32.
    Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.PubMedCrossRefGoogle Scholar
  33. 33.
    Dawson-Hughes B, Tosteson AN, Melton III LJ, Baim S, Favus MJ, Khosla S, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449–58.PubMedCrossRefGoogle Scholar
  34. 34.
    Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2005;56(3):178–88.PubMedGoogle Scholar
  35. 35.
    Official Positions of the International Society for Clinical Densitometry. 2007.
  36. 36.
    Muraki S, Yamamoto S, Ishibashi H, Horiuchi T, Hosoi T, Orimo H, et al. Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women. Osteoporos Int. 2004;15(9):724–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Tosteson AN, Melton III LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment ­thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–47.PubMedCrossRefGoogle Scholar
  38. 38.
    Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. South Med J. 2009;102(2):175–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477–501.PubMedCrossRefGoogle Scholar
  40. 40.
    Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ. 2002;166(12):1517–24.PubMedGoogle Scholar
  41. 41.
    MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76(4): 1536–8.PubMedCrossRefGoogle Scholar
  42. 42.
    LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc. 2004;5(2):98–100.PubMedCrossRefGoogle Scholar
  44. 44.
    Lee LT, Drake WM, Kendler DL. Intake of calcium and vitamin D in 3 Canadian long-term care facilities. J Am Diet Assoc. 2002;102(2):244–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92(4):1415–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Cranney A, Horsley T, O’Donnell S, Weiler HA, Puil L, Ooi DS et al. Effectiveness and safety of vitamin D in relation to bone health. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Evidence Report/Technology Assessment No. 158 (Prepared by the University of Ottawa Evidence-based Practice Center (UO-EPC) under Contract No. 290-02-0021. AHRQ Publication No. 07-E013.Google Scholar
  48. 48.
    Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–66.PubMedCrossRefGoogle Scholar
  49. 49.
    National Osteoporosis Foundation. Clinician’s guide to the prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation 2010.Google Scholar
  50. 50.
    Duncan DG, Beck SJ, Hood K, Johansen A. Using dietetic assistants to improve the outcome of hip fracture: a randomised controlled trial of nutritional support in an acute trauma ward. Age Ageing. 2006;35(2):148–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Avenell A, Handoll HH. A systematic review of protein and energy supplementation for hip fracture aftercare in older people. Eur J Clin Nutr. 2003;57(8):895–903.PubMedCrossRefGoogle Scholar
  52. 52.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291(16):1999–2006.PubMedCrossRefGoogle Scholar
  53. 53.
    Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997.Google Scholar
  54. 54.
    Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73(2):288–94.PubMedGoogle Scholar
  55. 55.
    Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Liu BA, Gordon M, Labranche JM, Murray TM, Vieth R, Shear NH. Seasonal prevalence of vitamin D deficiency in institutionalized older adults. J Am Geriatr Soc. 1997;45(5):598–603.PubMedGoogle Scholar
  57. 57.
    Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab. 2000;85(11):4125–30.PubMedCrossRefGoogle Scholar
  58. 58.
    Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64(1):9–13.PubMedCrossRefGoogle Scholar
  59. 59.
    Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int. 2000;67(1):10–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Wolff I, van Croonenborg JJ, Kemper HC, Kostense PJ, Twisk JW. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 1999;9(1):1–12.PubMedCrossRefGoogle Scholar
  62. 62.
    Kelley GA. Exercise and regional bone mineral density in postmenopausal women: a meta-analytic review of randomized trials. Am J Phys Med Rehabil. 1998;77(1):76–87.PubMedCrossRefGoogle Scholar
  63. 63.
    Papaioannou A, Adachi JD, Winegard K, Ferko N, Parkinson W, Cook RJ, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int. 2003;14(8): 677–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003;(4):CD000340.Google Scholar
  65. 65.
    Rubin C, Recker R, Cullen D, Ryaby J, McCabe J, McLeod K. Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res. 2004;19(3): 343–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Verschueren SM, Roelants M, Delecluse C, Swinnen S, Vanderschueren D, Boonen S. Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res. 2004;19(3):352–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Gusi N, Raimundo A, Leal A. Low-frequency vibratory exercise reduces the risk of bone fracture more than walking: a randomized controlled trial. BMC Musculoskelet Disord. 2006;7:92.PubMedCrossRefGoogle Scholar
  68. 68.
    Bonner Jr FJ, Sinaki M, Grabois M, Shipp KM, Lane JM, Lindsay R, et al. Health professional’s guide to rehabilitation of the patient with osteoporosis. Osteoporos Int. 2003;14 Suppl 2:S1–22.PubMedCrossRefGoogle Scholar
  69. 69.
    Carter ND, Khan KM, McKay HA, Petit MA, Waterman C, Heinonen A, et al. Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. CMAJ. 2002;167(9): 997–1004.PubMedGoogle Scholar
  70. 70.
    Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008;56(12): 2234–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, et al. Do hip protectors decrease the risk of hip fracture in institutional- and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2005;16:1461–74.PubMedCrossRefGoogle Scholar
  72. 72.
    Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev 2004;(3):CD001255.Google Scholar
  73. 73.
    Sinaki M. Critical appraisal of physical rehabilitation measures after osteoporotic vertebral fracture. Osteoporos Int. 2003;14(9): 773–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Handoll HH, Parker MJ, Sherrington C. Mobilisation strategies after hip fracture surgery in adults (Cochrane Review). Cochrane Database Syst Rev 2003;(1):CD001704.Google Scholar
  75. 75.
    Lamb SE, Morse RE, Evans JG. Mobility after proximal femoral fracture: the relevance of leg extensor power, postural sway and other factors. Age Ageing. 1995;24(4):308–14.PubMedCrossRefGoogle Scholar
  76. 76.
    Madsen OR, Lauridsen UB, Sorensen OH. Quadriceps strength in women with a previous hip fracture: relationships to physical ability and bone mass. Scand J Rehabil Med. 2000;32(1):37–40.PubMedCrossRefGoogle Scholar
  77. 77.
    Mitchell SL, Stott DJ, Martin BJ, Grant SJ. Randomized controlled trial of quadriceps training after proximal femoral fracture. Clin Rehabil. 2001;15(3):282–90.PubMedCrossRefGoogle Scholar
  78. 78.
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197–213.PubMedGoogle Scholar
  79. 79.
    Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD004523.Google Scholar
  80. 80.
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD001155.Google Scholar
  81. 81.
    Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42(5):841–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res. 2006;21(10):1503–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353–62.PubMedCrossRefGoogle Scholar
  84. 84.
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–50.PubMedCrossRefGoogle Scholar
  85. 85.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRefGoogle Scholar
  86. 86.
    Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23(4): 524–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedCrossRefGoogle Scholar
  88. 88.
    Cranney A, Wells GA. Hormone replacement therapy for postmenopausal osteoporosis. Clin Geriatr Med. 2003;19(2):361–70.PubMedCrossRefGoogle Scholar
  89. 89.
    Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am. 2002;31(3):659–79. xii.PubMedCrossRefGoogle Scholar
  90. 90.
    Chesnut III CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–76.PubMedCrossRefGoogle Scholar
  91. 91.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on ­fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.PubMedCrossRefGoogle Scholar
  92. 92.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55.PubMedCrossRefGoogle Scholar
  93. 93.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000;85(6):2129–34.PubMedCrossRefGoogle Scholar
  94. 94.
    Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O, et al. Treatment with Denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011.Google Scholar
  95. 95.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8): 756–65.PubMedCrossRefGoogle Scholar
  96. 96.
    Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3): 530–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009;182(6):2670–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.PubMedCrossRefGoogle Scholar
  99. 99.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–82.PubMedCrossRefGoogle Scholar
  100. 100.
    Jamal S, Ljunggren O, Stehman-Breen C, Cummings S, McClung M, Goemaere S, et al. The effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011.Google Scholar
  101. 101.
    Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1–34.PubMedGoogle Scholar
  102. 102.
    Giangregorio LM, Jantzi M, Papaioannou A, Hirdes J, Maxwell CJ, Poss JW. Osteoporosis management among residents living in long-term care. Osteoporos Int. 2009;20(9):1471–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–24.PubMedCrossRefGoogle Scholar
  104. 104.
    Boonen S, McClung MR, Eastell R, El-Hajj FG, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004;52(11):1832–9.PubMedCrossRefGoogle Scholar
  105. 105.
    The Washington Manual of Medical Therapeutics. 31st ed. St. Louis: Lippincott, Williams and Wilkins; 2004.Google Scholar
  106. 106.
    Holick MF. Vitamin D deficiency: what a pain it is. Mayo Clin Proc. 2003;78(12):1457–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Reginato AJ, Coquia JA. Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol. 2003;17(6):1063–80.PubMedCrossRefGoogle Scholar
  108. 108.
    Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med. 2000;108(4):296–300.PubMedCrossRefGoogle Scholar
  109. 109.
    Passeri G, Pini G, Troiano L, Vescovini R, Sansoni P, Passeri M, et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab. 2003;88(11):5109–15.PubMedCrossRefGoogle Scholar
  110. 110.
    Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005;135(2):332–7.PubMedGoogle Scholar
  111. 111.
    Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204–10.PubMedGoogle Scholar
  112. 112.
    Bischoff-Ferrari HA. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int. 2007;18(4):401–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13(3):257–64.PubMedCrossRefGoogle Scholar
  114. 114.
    Mawer EB, Davies M. Vitamin D nutrition and bone disease in adults. Rev Endocr Metab Disord. 2001;2(2):153–64.PubMedCrossRefGoogle Scholar
  115. 115.
    Tebben PJ, Kumar R. Fanconi syndrome and renal tubular acidosis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society of Bone and Mineral Research; 2003. p. 426–30.Google Scholar
  116. 116.
    Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ. 2005;330(7490): 524–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ. 2005;330(7490):524–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl. 2009;76 Suppl 113:S1–130.Google Scholar
  119. 119.
    Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res. 2006;21 Suppl 2:94–8.CrossRefGoogle Scholar
  120. 120.
    Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res. 2001;16(8):1379–87.PubMedCrossRefGoogle Scholar
  121. 121.
    van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res. 2002;17(3):465–71.PubMedCrossRefGoogle Scholar
  122. 122.
    Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget’s disease of bone. J Bone Miner Res. 2006;21 Suppl 2:58–63.CrossRefGoogle Scholar
  123. 123.
    Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget’s disease of bone. J Bone Miner Res. 2006;21 Suppl 2:38–44.CrossRefGoogle Scholar
  124. 124.
    Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget’s disease of bone. J Bone Miner Res. 2006;21 Suppl 2:3–8.CrossRefGoogle Scholar
  125. 125.
    Barker DJ, Clough PW, Guyer PB, Gardner MJ. Paget’s disease of bone in 14 British towns. Br Med J. 1977;1(6070):1181–3.PubMedCrossRefGoogle Scholar
  126. 126.
    Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget’s disease of bone: the Lancashire focus. Br Med J. 1980;280(6222): 1105–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Selby PL. Guidelines for the diagnosis and management of Paget’s disease: a UK perspective. J Bone Miner Res. 2006;21 Suppl 2:92–3.CrossRefGoogle Scholar
  128. 128.
    Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab. 1996;81(3):961–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study Group. Am J Med. 1999;106(5): 513–20.PubMedCrossRefGoogle Scholar
  130. 130.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Siris ES. Perspectives: a practical guide to the use of pamidronate in the treatment of Paget’s disease. J Bone Miner Res. 1994;9(3):303–4.PubMedCrossRefGoogle Scholar
  132. 132.
    DeRose J, Singer FR, Avramides A, Flores A, Dziadiw R, Baker RK, et al. Response of Paget’s disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med. 1974;56(6): 858–66.PubMedCrossRefGoogle Scholar
  133. 133.
    Liberman UA, Marx SJ. Vitamin D-dependent rickets. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society of Bone and Mineral Research; 2003. p. 407–13.Google Scholar
  134. 134.
    Blumsohn A. What have we learnt about the regulation of phosphate metabolism? Curr Opin Nephrol Hypertens. 2004;13(4):397–401.PubMedCrossRefGoogle Scholar
  135. 135.
    Reinke CM, Breitkreutz J, Leuenberger H. Aluminium in over-the-counter drugs: risks outweigh benefits? Drug Saf. 2003;26(14): 1011–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Juravinski Research CentreSt. Peter’s HospitalHamiltonCanada

Personalised recommendations